查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593894

肺癌藥物市場：依疾病、分子、通路分類 - 全球預測 2025-2030

Lung Cancer Drugs Market by Disease (Non-Small Cell Lung Cancer, Small Cell Lung cancer), Molecule (Biologics, Small Molecules), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺癌治療市值為247.6億美元，預計到2024年將達到269.8億美元，複合年成長率為9.06%，到2030年將達到454.5億美元。

肺癌藥物的範圍包括旨在治療不同類型肺癌的廣泛治療和介入措施，包括非小細胞肺癌（NSCLC）和小細胞肺癌（SCLC）。這些治療範圍從傳統的化療和放射線治療到尖端的免疫療法和分子標靶治療。全球與肺癌相關的高盛行率和死亡率凸顯了對肺癌治療的需求。其應用範圍從初級治療到安寧療護，最終用途主要是醫院、癌症研究機構和提供癌症治療的專業中心。該市場的關鍵成長要素包括由於吸煙和空氣污染導致的肺癌發病率增加、個人化醫療的進步以及生物相似藥的採用增加。最新的商機來自次世代定序和 CRISPR 技術的持續發展，為根據個人基因圖譜量身定做的精準醫療鋪平了道路，有可能改善治療結果。此外，新興市場醫療保健基礎設施的成長正在創造新的擴張機會。然而，挑戰依然存在，包括高昂的藥品成本、嚴格的法律規範以及漫長的臨床試驗帶來的巨大財務負擔，這些可能會阻礙市場進入。創新可以集中於識別生物標記、研究抗藥性機制以及提高現有藥物有效性的聯合治療。探索聯盟和收購以加強研發能力也可能有益。市場的本質是動態和競爭的，受到不斷的科學發現以及生物相似藥和學名藥的進入造成價格競爭的推動。該領域的成功需要對研發進行策略性投資、對監管環境的深入了解以及開拓服務於多元化全球市場的強大分銷網路。

主要市場統計
基準年[2023] 247.6億美元
預測年份 [2024] 269.8億美元
預測年份 [2030] 454.5億美元
複合年成長率（%） 9.06%

市場動態：揭示快速發展的肺癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變肺癌藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 肺癌患者增加
    • 消費者對標靶治療治療的需求不斷成長
    • 全球吸菸者人數不斷增加
    • 政府對肺癌控制的有利支持
  • 市場限制因素
    • 肺癌藥物的副作用
  • 市場機會
    • 正在進行的肺癌治療研究活動
    • 新藥領域技術進步
  • 市場挑戰
    • 生物製藥和標靶治療的可用性以及肺癌治療成本的上升

波特五力：駕馭肺癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對肺癌藥物市場的影響

外部宏觀環境因素對肺癌治療藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肺癌治療藥物市場的競爭狀況

肺癌治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 肺癌藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估肺癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃肺癌藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對肺癌藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肺癌病例數和發生率不斷增加
      • 消費者對標靶治療的需求不斷成長
      • 全球吸菸者人數不斷增加
      • 政府對肺癌控制的有利支持
    • 抑制因素
      • 肺癌藥物的副作用
    • 機會
      • 正在進行的肺癌治療研究活動
      • 新藥領域技術進步
    • 任務
      • 生物製藥和標靶治療的可用性以及肺癌治療的高成本
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肺癌治療藥物市場：依疾病分類

  • 非小細胞肺癌
  • 小細胞肺癌

第7章 按分子分類的肺癌藥物市場

  • 生物製藥
  • 小分子

第8章肺癌治療藥物市場：依分銷管道分類

  • 離線
  • 線上

第9章北美和南美肺癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太肺癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲肺癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly & Company Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-434CCDA05288

The Lung Cancer Drugs Market was valued at USD 24.76 billion in 2023, expected to reach USD 26.98 billion in 2024, and is projected to grow at a CAGR of 9.06%, to USD 45.45 billion by 2030.

The scope of lung cancer drugs encompasses a broad array of therapeutics and interventions aimed at treating various types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These treatments range from traditional chemotherapy and radiation therapies to cutting-edge immunotherapies and targeted treatments. The necessity of lung cancer drugs is underscored by the high prevalence and mortality rates associated with lung cancer globally. Their application spans from initial treatments to palliative care, and end-use primarily involves hospitals, cancer research institutes, and specialty centers providing oncology care. Key growth influences in this market include increasing incidences of lung cancer due to smoking and air pollution, advancements in personalized medicine, and the rising adoption of biosimilars. The latest opportunities arise with the ongoing development of next-generation sequencing and CRISPR technology, which open avenues for precision medicine tailored to individual genetic profiles, potentially improving treatment outcomes. Additionally, the growth of healthcare infrastructure in emerging markets presents new opportunities for expansion. However, challenges persist, such as high drug costs, stringent regulatory frameworks, and the significant financial burden associated with lengthy clinical trials, which may hinder market access. Innovation can focus on research into biomarker identification, drug resistance mechanisms, and combination therapies that enhance the efficacy of existing drugs. Exploring partnerships or acquisitions to bolster R&D capabilities may also prove beneficial. The market's nature is dynamic and competitive, driven by continuous scientific discoveries and the entry of biosimilars and generics that create price competition. Success in this arena demands strategic investments in R&D and a keen understanding of regulatory landscapes, along with developing robust distribution networks to reach diverse global markets.

KEY MARKET STATISTICS
Base Year [2023] USD 24.76 billion
Estimated Year [2024] USD 26.98 billion
Forecast Year [2030] USD 45.45 billion
CAGR (%) 9.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Drugs Market

The Lung Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases and incidences of lung cancer
    • Growing demand for the targeted therapies by consumers
    • Increase in the number of smokers across the globe
    • Favorable government support to control lung cancer
  • Market Restraints
    • Side effects of lung cancer drugs
  • Market Opportunities
    • Ongoing research activities in the lung cancer treatments
    • Technological advancement in the fields of novel drugs
  • Market Challenges
    • Availability of biologics & targeted therapies and high cost of lung cancer treatments

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Drugs Market

A detailed market share analysis in the Lung Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Drugs Market

A strategic analysis of the Lung Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly & Company Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease, market is studied across Non-Small Cell Lung Cancer and Small Cell Lung cancer.
  • Based on Molecule, market is studied across Biologics and Small Molecules.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases and incidences of lung cancer
      • 5.1.1.2. Growing demand for the targeted therapies by consumers
      • 5.1.1.3. Increase in the number of smokers across the globe
      • 5.1.1.4. Favorable government support to control lung cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of lung cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities in the lung cancer treatments
      • 5.1.3.2. Technological advancement in the fields of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of biologics & targeted therapies and high cost of lung cancer treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lung Cancer Drugs Market, by Disease

  • 6.1. Introduction
  • 6.2. Non-Small Cell Lung Cancer
  • 6.3. Small Cell Lung cancer

7. Lung Cancer Drugs Market, by Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Lung Cancer Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Lung Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lung Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lung Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim GmbH
  • 4. Bristol-Myers Squibb Company
  • 5. Eli Lilly & Company Ltd.
  • 6. F. Hoffmann-La Roche AG
  • 7. GlaxoSmithKline PLC
  • 8. Incyte Corporation
  • 9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023